Sarepta Therapeutics' gene therapy Elevidys for Duchenne muscular dystrophy is currently halted at FDA request amid safety concerns linked to patient deaths. Families and clinicians are grappling with the impact of treatment suspensions and an uncertain regulatory path, with the FDA indicating Sarepta must conduct new studies to confirm Elevidys' safety. Concurrent company layoffs and internal turmoil compound the situation. Roche has also ceased shipments of Elevidys in several countries, although it continues in some markets outside the US. Sarepta's financial and operational outlook remains precarious amid these developments.